Clinical Trial Search

Phase 3 N=38 Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia

Friedreich's Ataxia

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs — 21; 7; 0; 0 participants

Amgen Results May 2018 0.0% serious AE View details

Phase 3 N=33 Usability of an AI for M923 in Subjects With Moderate to Severe RA

Rheumatoid Arthritis

Primary: Usability of the Auto-injector (AI) at Week 4 — 8.15; 8.17; 9.27; 8.12 Scores on a scale

Momenta Pharmaceuticals, Inc. Results May 2018 6.1% serious AE View details

Phase 3 N=720 Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge

Analgesia After ED Discharge for Extremity Injuries

Primary: Difference in Pain Intensity Score Before and After Last Dose. — 7.6; 7.6; 7.9; 7.9 units on a scale

Montefiore Medical Center Results May 2018 0.0% serious AE View details

Phase 3 N=734 Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)

Human Immunodeficiency Virus (HIV)

Primary: Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 — 84.3; 80.8 Percentage of Participants

Merck Sharp & Dohme LLC Results Apr 2018 5.8% serious AE View details

Phase 3 N=86 OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis

Chronic Allergic Conjunctivitis

Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 — 2.04; 2.31 units on a scale

Ocular Therapeutix, Inc. Results Apr 2018 0.0% serious AE View details

Phase 3 N=673 Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

Primary: Number of Participants Who Did Not Experience a Flare During Period 2 by Week 68 — 72; 107 Participants — p=<0.001

AbbVie Results Apr 2018 3.5% serious AE View details

Phase 3 N=1,056 A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor

Major Depressive Disorder

Primary: Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -8.73; -8.49 units on a scale — p=0.751

Eli Lilly and Company Results Apr 2018 1.6% serious AE View details

Phase 3 N=424 A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand) — -1.34; -1.21; -0.54 percentage of HbA1c — p=<.001

Eli Lilly and Company Results Apr 2018 3.1% serious AE View details

Phase 3 N=800 Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects

Acne Vulgaris

Primary: Absolute Change From Baseline to Week 12 in Total Lesion Counts. — -57.2; -60.8; -49.8 lesion count — p=<0.001

GlaxoSmithKline Results Apr 2018 0.0% serious AE View details

Phase 3 N=1,004 A Rheumatoid Arthritis Study in Participants

Rheumatoid Arthritis

Primary: Percentage of Participants With American College of Rheumatology 20% (ACR20) Response — 34.4; 33.5; 31.5 percentage of participants

Eli Lilly and Company Results Apr 2018 3.3% serious AE View details

Phase 3 N=1,480 A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

Major Depressive Disorder (MDD)

Primary: Change From Randomization to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.36; -9.59; -9.36 units on a scale — p=0.997

Eli Lilly and Company Results Apr 2018 0.6% serious AE View details

Phase 3 N=406 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Bladder Cancer

Primary: Disease Recurrence Rate — 27.86; 40 percentage of patients with recurrence — p=0.01

SWOG Cancer Research Network Results Apr 2018 3.5% serious AE View details

Phase 3 N=35 Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder

Overactive Bladder · Urinary Incontinence

Primary: Response to Urinary Incontinence as a Composite Measure of Efficacy of add-on Mirabegron — 12; 23 Participants

CHU de Quebec-Universite Laval Results Apr 2018 0.0% serious AE View details

Phase 3 N=830 Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

Herpes Zoster

Primary: Number of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in GSK1437173A Group — 361 Participants

GlaxoSmithKline Results Apr 2018 6.3% serious AE View details

Phase 3 N=125 Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Hereditary Angioedema (HAE)

Primary: Rate of Investigator Confirmed Hereditary Angioedema (HAE) Attacks During Treatment Period — 1.967; 0.480; 0.526; 0.257 Attacks per 4 weeks — p=<0.001

Shire Results Apr 2018 4.8% serious AE View details